News BIOLASE, Inc.

Equities

BIOL

US0909117022

Delayed Nasdaq Other stock markets 01:33:10 2024-04-23 pm EDT			5-day change	1st Jan Change
0.1515 ^USD	+1.00%		+12.31%	-86.26%

Apr. 01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
Mar. 22	Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	Apr. 01	MT
Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday	Mar. 22	MT
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday	Mar. 22	MT
Top Premarket Gainers	Mar. 22	MT
Biolase: Q4 Earnings Snapshot	Mar. 21	AQ
Transcript : BIOLASE, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 21	CI
BIOLASE, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
BIOLASE TO REPORT FOURTH QUARTER AND FULL YEAR 2023 RESULTS ON MARCH 21, 2024	Mar. 15	AQ
BIOLASE LAUNCHES STATE-OF-THE-ART ALL-TISSUE LASER SYSTEM TO ACCELERATE ADOPTION OF LASERS IN DENTISTRY	Feb. 23	AQ
BIOLASE ANNOUNCES FIRST QUARTER 2024 WEBINAR SERIES 'LETS TALK DENTAL'	Feb. 21	AQ
BIOLASE, INC. GRANTED EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH THE STOCKHOLDERS EQUITY CONTINUED LISTING REQUIREMENT	Feb. 15	AQ
Biolase Prices $7 Million Public Offering	Feb. 13	MT
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024	Jan. 30	AQ
BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023	Jan. 29	CI
BIOLASE, Inc. Provides Earnings Guidance for the Year 2024	Jan. 29	CI
Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc	Dec. 29	CI
BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial	Dec. 12	CI
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Dec. 06	PR
Biolase, Inc. Enters into the Eleventh Amendment to Credit Agreement with SWK Funding LLC	Nov. 17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BIOLASE, Inc.

Equities

BIOL

US0909117022

Summary

Filters